UK's Syncona gains after Beacon gene therapy trial meets endpoint

Syncona

21/09/2026 08:53

** Shares of British healthcare investment firm Syncona SYNCS.L up 6% at 118 pence
** Co says portfolio company Beacon Therapeutics' Phase II/III VISTA trial meets FDA-endorsed primary endpoint for gene therapy laru-zova
** Response rate was 31% in the high-dose arm and 24.1% in the low-dose arm
** Data supports Beacon's plans to begin regulatory discussions and start a rolling US biologics licence application submission later in 2026
** YTD, stock is up ~24%

 (Reporting by Neeshita Beura in Bengaluru)
 ((Neeshita.Beura@thomsonreuters.com))